HIV/AIDS Clinical Trial
— POCOfficial title:
Reaching 90% Target of HIV Viral Suppression: The Role of Point-of-Care Viral Load Monitoring in Resource-Constrained Settings in Nigeria
Verified date | March 2021 |
Source | Harvard School of Public Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The UNAIDS 90-90-90 goals represents an ambitious strategy to end the acquired immunodeficiency syndrome (AIDS) epidemic by 2020 [UNAIDS, 2015]. While viral load (VL) quantification is the gold standard of HIV treatment monitoring, it is only routinely available and employed in resource-rich countries. The use of an affordable, reliable, point-of-care (POC) VL assay has been considered a "game-changer", where increased access, minimal lab worker training, and same day results could be addressed in a single solution. To date, POC VL assays have been evaluated by their manufacturers with reference panels of samples with some in-country laboratory evaluations. While these are appropriate and critical first steps, it is also important to evaluate the impact of this new technology against the standard of care (SOC) method of VL monitoring in an actual resource-limited setting. Nigeria has the second highest burden of HIV in the world, with an estimated 3.2 million infected and serves as a relevant setting for testing feasibility and efficacy of POC VL monitoring [UNAIDS, 2016]. In order to present the case for implementing the use of POC VL testing across Nigeria, data on the acceptability, feasibility and efficacy of using POC testing for VL monitoring are needed. To address this need, the investigators have designed a randomized controlled trial comparing POC VL to monitoring to the SOC, which follows the Nigerian National Guidelines, to provide operational evidence for implementation of POC VL testing in Nigeria. This trial is aimed at testing the hypothesis that using POC versus SOC VL monitoring in HIV-infected patients newly initiating ART will improve overall ART outcomes, increase ART adherence and program retention rates, and result in faster switches to second-line treatment of patients failing first-line ART.
Status | Completed |
Enrollment | 543 |
Est. completion date | February 28, 2021 |
Est. primary completion date | February 28, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: -All HIV-infected patients newly initiating ART Exclusion Criteria: - Previous ARV experience - Pregnant |
Country | Name | City | State |
---|---|---|---|
Nigeria | Jos University Teaching Hospital | Jos | Plateau |
Nigeria | Comprehensive Health Care Centre, Zamko | Zamko | Plateau |
Lead Sponsor | Collaborator |
---|---|
Harvard School of Public Health | Centers for Disease Control and Prevention, Jos University Teaching Hospital |
Nigeria,
Fonjungo PN, Boeras DI, Zeh C, Alexander H, Parekh BS, Nkengasong JN. Access and Quality of HIV-Related Point-of-Care Diagnostic Testing in Global Health Programs. Clin Infect Dis. 2016 Feb 1;62(3):369-374. doi: 10.1093/cid/civ866. Epub 2015 Sep 30. Review. — View Citation
Fonjungo PN, Osmanov S, Kuritsky J, Ndihokubwayo JB, Bachanas P, Peeling RW, Timperi R, Fine G, Stevens W, Habiyambere V, Nkengasong JN. Ensuring quality: a key consideration in scaling-up HIV-related point-of-care testing programs. AIDS. 2016 May 15;30(8):1317-23. doi: 10.1097/QAD.0000000000001031. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with VL<1000 copies/mL at month 12 post-initiation of ART (range 11-15 months) in SOC VL versus POC VL | Proportion of patients that have undetectable viral load at the end of observation (month 12) will be compared by treatment arm | 12 months (range 11-15 months) | |
Secondary | Difference in ART adherence patterns in patients in the SOC versus POC VL arms | Average percent adherence will be computed using patient refill data that are stored electronically. The average will be calculated as number of days supplied over total days in the given time interval, adjusting for amount of medication that should remain since last refill, computed based on amount supplied during the previous visit minus the number of days since the last visit. | From ART initiation to month 12 | |
Secondary | Difference in loss to follow-up rates by 12 months post-initiation of ART between patients monitored with SOC versus POC VL arms | LTFU at month 12 is defined as not having made any refill pick-ups or clinical visits since 9-month post-initiation of ART. | Month 12 | |
Secondary | Impact of trial site on differences in virologic suppression rates within patients receiving SOC VL monitoring | Comparison of data from two different trial sites | Month 12 | |
Secondary | Difference in time from ART initiation to the confirmation of virologic failure in SOC versus POC VL monitoring arms | Subset analysis in those that experienced virologic failure (confirmed) | ART Initiation to Month 12 | |
Secondary | Difference in time from ART initiation to switch to 2L treatment in patients in VF in SOC versus POC VL monitoring arms | Subset analysis in those that experienced virologic failure (confirmed) | ART Initiation to Month 12 | |
Secondary | Difference in time from specimen collection to availability of VL results in patient charts in SOC versus POC VL monitoring arms | Comparison of time from specimen collection to the time the result is entered into the patient chart by treatment arm | All follow-up visits at which VL monitored up to Month 12 | |
Secondary | Difference in time from specimen collection to delivery of VL results to patient in SOC versus POC VL monitoring arms | Comparison of time from specimen collection to the time the result is verbally conveyed to the patient by their clinician by treatment arm | All follow-up visits at which VL monitored up to Month 12 | |
Secondary | Difference in time from lab confirmation of first unsuppressed VL to adherence counseling provided and switch to 2L in SOC versus POC VL monitoring arms | Subset analysis in those that experienced virologic failure (confirmed) | All follow-up visits at which VL monitored up to Month 12 | |
Secondary | Difference in HIV DRM patterns in patients failing 1L ART in the SOC versus POC VL monitoring arm | Subset analysis in those that experienced virologic failure (confirmed) | Month 12 | |
Secondary | Health care worker (HCW) satisfaction level with POC versus SOC VL monitoring | Health care workers will complete a standardized survey querying about their satisfaction with the POC assay. The survey uses a scale measuring agreement level. The scale ranges from 0 to 5 where 0=not applicable, 1=strongly disagree and 5=strongly agree | Month 12 | |
Secondary | POC VL arm patient satisfaction with POC vs SOC VL testing | POC VL arm patients will be queried using a standardized survey about their satisfaction with the POC VL assay. The survey uses a scale measuring agreement level. The scale ranges from 0 to 5 where 0=not applicable, 1=strongly disagree and 5=strongly agree. | Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|